drugset / Trial / NCT01469338
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
Phase 2
Terminated
9 enrolled
University of Southern California
National Cancer Institute (NCI) · collabSanofi · collab
NaSingle-groupOpen-labelSupportive care
Summary
This phase II trial studies how well octreotide works in reducing diarrhea in patients receiving cabazitaxel and prednisone for hormone-resistant prostate cancer (HRPC) previously treated with docetaxel. Octreotide may prevent diarrhea by blocking the secretion of several hormones in patients receiving chemotherapy for prostate cancer
Timeline
- Start
- 2012-07
- Primary completion
- 2014-10
- Completion
- 2014-11
Outcome
Outcome not reported
Stopped (Business): “lack of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Octreotide | Peptide | — | Subcutaneous |
| Subject | octreotide pamoate | Unknown | — | Intramuscular |
| Background | Cabazitaxel | Other / unclassified | — | Intravenous |
| Background | Prednisone | Other / unclassified | — | Oral |